Aviceda Therapeutics GA drug into Phase II trials despite endpoint miss
December 17, 2025

Aviceda to Advance GA Drug into Phase III Trials Despite Phase IIb Primary Endpoint Miss

Lesions aside, functional vision keeps AVD-104 in the GA therapy race.  In geographic atrophy (GA) drug development, a missed primary…

Discover our fascinating content at issuu

explore